January 12-15 | San Francisco Marriott Marquis
January 12-16 | Virtual
AceLink Therapeutics
AceLink is a clinical-stage drug development company. Leveraging our expertise in glycolipid biology, we develop drugs for glycolipid storage diseases and genetic Parkinson disease. Leading molecule AL1211 is in Phase 2 clinical trial for Fabry disease.